FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution
This article was originally published in The Pink Sheet Daily
Executive Summary
Culture change, not congressional action is needed advance this step toward faster drug development, FDA’s drug leader tells Energy & Commerce Committee.
You may also be interested in...
Reliance On ‘Digitized Paper’ Is Slowing Drug Development – US FDA’s Woodcock
Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital age, CDER director says, challenging industry, regulators and others to creatively think about how to move away from legacy, paper-based processes in clinical trials and regulatory submissions.
Major Pharmas To Collaborate In Non-Profit Initiative To Resolve Clinical Development Hurdles
Called TransCelerate BioPharma, the initiative funded by 10 big drug firms will work to develop uniform clinical data standards and certification for trial sites and investigators, with deliverables expected by mid-2013.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.